Biodexa Pharmaceuticals (BDRX) announced the European Commission has granted Orphan Drug Designation for eRapa in familial adenomatous polyposis. The company said the Phase 3 study of eRapa in FAP is in the final stages of implementation.
"This Orphan Drug Designation is another important step as we move our FAP program forward into a registrational Phase 3 study," said Stephen Stamp, CEO and CFO of Biodexa Pharmaceuticals.
Shares of Biodexa Pharmaceuticals are down 15% in pre-market trade on Monday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.